Cargando…

Serum metalloproteinases and their inhibitors: markers for malignant potential.

Death from cancer results from the development of metastases or local progression of tumour. Metastasis and local progression may result from the inappropriate activity of metalloproteinases released by tumour cells or of their regulatory peptides. We have developed quantitative assays for interstit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baker, T., Tickle, S., Wasan, H., Docherty, A., Isenberg, D., Waxman, J.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1994
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033376/ https://www.ncbi.nlm.nih.gov/pubmed/8080738

Ejemplares similares

Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck
por: Chaudhary, Ajay Kumar, et al.
Publicado: (2010)

A serum factor with potential as a tumour marker in malignant lymphoma.
por: Begent, R. H., et al.
Publicado: (1980)

The Effect of Imiquimod on Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Malignant Melanoma Cell Invasion
por: Jung, Jin Young, et al.
Publicado: (2014)

Serum tissue inhibitor of matrix metalloproteinase-1 levels are associated with mortality in patients with malignant middle cerebral artery infarction
por: Lorente, Leonardo, et al.
Publicado: (2015)

Bone-Seeking Matrix Metalloproteinase Inhibitors for the Treatment of Skeletal Malignancy
por: Laghezza, Antonio, et al.
Publicado: (2020)

Relationship between Serum Levels of Metalloproteinase-8 and Tissue Inhibitor of Metalloproteinases-1 and Exercise Test Results in Postmenopausal Women
por: Mieczkowska, J., et al.
Publicado: (2016)

Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma
por: Štrbac, Danijela, et al.
Publicado: (2019)

Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics
por: Raeeszadeh-Sarmazdeh, Maryam, et al.
Publicado: (2020)

Imbalances between Matrix Metalloproteinases (MMPs) and Tissue Inhibitor of Metalloproteinases (TIMPs) in Maternal Serum during Preterm Labor
por: Tency, Inge, et al.
Publicado: (2012)

Changes in Serum Levels of Matrix Metalloproteinase-1 and Tissue Inhibitor of Metalloproteinases-1 in Patients with Essential Hypertension
por: Kostov, Krasimir, et al.
Publicado: (2022)

Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis
por: Tanaka, Komei, et al.
Publicado: (2013)

Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases Are Potential Biomarkers of Pulmonary and Extra-Pulmonary Tuberculosis
por: Kathamuthu, Gokul Raj, et al.
Publicado: (2020)

Selected Metal Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases as Potential Biomarkers for Tubulointerstitial Fibrosis in Children with Unilateral Hydronephrosis
por: Bieniaś, Beata, et al.
Publicado: (2020)

Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas.
por: Urbanski, S. J., et al.
Publicado: (1992)

High serum levels of tissue inhibitor of matrix metalloproteinase-1 during the first week of a malignant middle cerebral artery infarction in non-surviving patients
por: Lorente, Leonardo, et al.
Publicado: (2019)

Engineering of tissue inhibitor of metalloproteinases mutants as potential therapeutics
por: Nagase, Hideaki, et al.
Publicado: (2002)

Are Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Useful as Markers in Diagnostic Management of Children with Newly Diagnosed Ulcerative Colitis?
por: Czajkowska, Aleksandra, et al.
Publicado: (2022)

Polymerizable Matrix Metalloproteinases’ Inhibitors with Potential Application for Dental Restorations
por: Laronha, Helena, et al.
Publicado: (2021)

Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer.
por: Gohji, K., et al.
Publicado: (1998)

Serum levels and tissue expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinases 2 (TIMP-2) in colorectal cancer patients
por: Groblewska, Magdalena, et al.
Publicado: (2014)

Tissue inhibitors of metalloproteinases
por: Murphy, Gillian
Publicado: (2011)

Urinary metalloproteinases and tissue inhibitors of metalloproteinases as potential early biomarkers for renal fibrosis in children with nephrotic syndrome
por: Bieniaś, Beata, et al.
Publicado: (2018)

Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Echinoderms: Structure and Possible Functions
por: Dolmatov, Igor Yu., et al.
Publicado: (2021)

Imbalance of tissue inhibitors of metalloproteinases (TIMP) – 1 and – 4 serum levels, in patients with inflammatory bowel disease
por: Kapsoritakis, Andreas N, et al.
Publicado: (2008)

Assessment of serum concentrations of matrix metalloproteinase 1, matrix metalloproteinase 2 and tissue inhibitors of metalloproteinases 1 in atopic dermatitis in correlation with disease severity and epidermal barrier parameters
por: Basałygo, Magdalena, et al.
Publicado: (2021)

Role of tissue inhibitors of metalloproteinases (TIMPs) in colorectal carcinoma.
por: Joo, Y. E., et al.
Publicado: (1999)

Serum Immunoglobulins as Diagnostic Markers in Smokeless Tobacco Users for Prevention of Oral Potentially Malignant Disorders
por: Shukla, Anjani Kumar, et al.
Publicado: (2020)

Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer
por: Sakakibara, T, et al.
Publicado: (2005)

Production of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Human Breast Carcinomas
por: Iwata, Hiroji, et al.
Publicado: (1996)

Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in the hair cycle
por: HOU, CHUN, et al.
Publicado: (2016)

Tissue inhibitor of metalloproteinase-1 and interleukin-10 in serum from naïve and scrapie infected sheep
por: Silva, Marta G., et al.
Publicado: (2019)

Matrix Metalloproteinases in Chemoresistance: Regulatory Roles, Molecular Interactions, and Potential Inhibitors
por: Tune, Bernadette Xin Jie, et al.
Publicado: (2022)

Matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2, and transforming growth factor beta 1 in the aqueous humor and serum of patients with pseudoexfoliation syndrome
por: Kara, Selcuk, et al.
Publicado: (2014)

Effect of prostaglandin analogs on matrix metalloproteinases and tissue inhibitor of metalloproteinases in eyelid muscle specimens
por: Karli, Sapir, et al.
Publicado: (2018)

Evaluation of serum neopterin, periostin, Tenascin‐C, tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-2 levels in obese pregnant women
por: Melekoğlu, Rauf, et al.
Publicado: (2022)

Bimatoprost, latanoprost, and tafluprost induce differential expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases
por: Yamada, Hiroshi, et al.
Publicado: (2016)

Expression of matrix metalloproteinase-9 in oral potentially malignant disorders: A systematic review
por: Venugopal, Archana, et al.
Publicado: (2016)

Levels of matrix metalloproteinases differ in plasma and serum – aspects regarding analysis of biological markers in cancer
por: Jonsson, Andreas, et al.
Publicado: (2016)

Serum matrix metalloproteinase 9 (MMP9) as a biochemical marker for wasting marmoset syndrome
por: YOSHIMOTO, Takuro, et al.
Publicado: (2016)

Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans.
por: Kossakowska, A. E., et al.
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_vbn5lq817sav45gp5bfunl7dgi